Clients News • MC Services corporate website
5522
paged,page-template-default,page,page-id-5522,paged-4,page-paged-4,bridge-core-2.1.4,qode-listing-1.0.1,qode-social-login-1.0,qode-quick-links-1.0,ajax_fade,page_not_loaded,,qode-title-hidden,paspartu_enabled,qode_grid_1400,footer_responsive_adv,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-20.1,qode-theme-bridge,disabled_footer_top,qode_header_in_grid,bridge-child,wpb-js-composer js-comp-ver-6.5.0,vc_responsive

CLIENT NEWS

 

 

  • InflaRx Announces Positive Topline Results for Vilobelimab from the U.S. Phase II ANCA-Associated Vasculitis IXPLORE Study
    12 May 2021
    www.inflarx.de
  • CatalYm GmbH: CatalYm Appoints Industry Leader Dr. Phil L’Huillier as Chief Executive Officer
    04 May 2021
    www.catalym.com
  • HeartBeat.bio AG to Reinvent Cardiac Drug Discovery
    04 May 2021
    www.heartbeat.bio
  • VAXIMM Announces Participation at Scientific and Industry Events in May
    04 May 2021
    www.vaximm.com
  • Relief and Applied Pharma Research (APR) Sign Binding Term Sheet for Relief to Acquire All Outstanding Shares of APR
    04 May 2021
    www.relieftherapeutics.com
  • Newron announces Paragraph IV ANDA filing for Xadago(R) (safinamide) in the USA
    04 May 2021
    www.newron.com
  • Heidelberg Pharma AG: Interim Management Statement on the First Three Months of 2021
    29 April 2021
    www.heidelberg-pharma.com
  • Vetter and Rentschler Biopharma Further Strengthen their Strategic Alliance
    28 April 2021
    www.rentschler-biopharma.com
  • XPhyto Pursues Market Access in Israel for its COVID-19 PCR Rapid Test
    28 April 2021
    www.xphyto.com
  • Relief and AdVita Announce Initiation of Phase 2 Trial with Inhaled RLF-100 for the Prevention of COVID-19-related Acute Respiratory Distress Syndrome
    22 April 2021
    www.relieftherapeutics.com